Investors

For the astute biotechnology investor, Patrys offers a compelling opportunity. Our Deoxymab platform is a novel antibody exploiting synthetic lethality to fight cancer. So why is this unique? It targets cancer and is attracted to the DNA released from tumours; it has multiple modes of action to block several DDR systems; it has an excellent side-effect profile; and importantly, can cross the blood-brain barrier too.

Our shareholders are valued partners in our Company – explore our Investors Centre to learn more, subscribe to our email updates and we’ll keep you updated with our progress as we bring this exciting treatment to life.

Latest news

Working with partners, collaborators and investors around the world, we believe that we are ideally positioned to leverage the unique attributes of deoxymabs. Thank you for your support.

Patrys CEO & MD, Dr James Campbell

Working with partners, collaborators and investors around the world, we believe that we are ideally positioned to leverage the unique attributes of deoxymabs. Thank you for your support.

Patrys CEO & MD, Dr James Campbell

Menu